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LETTERS
During a pandemic, when supplies are 
unavailable, the balance of benefit to 
harm would favor using the expired 
product. 
The 1918 influenza pandemic is 
estimated  to  have  killed  50  million 
persons worldwide (10), many in de-
veloping  countries.  By  better  safe-
guarding  available  drug  stockpiles, 
more drugs could be made available to 
poorer countries that have few drugs 
stockpiled. 
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Intrafamilial  
Transmission of  
Methicillin-Resistant   
Staphylococcus  
aureus1
To  the  Editor:  Community-ac-
quired methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) infection 
was first described in our region over 
15 years ago (1). More recently, CA-
MRSA has become a global concern 
and is now a common cause of skin 
and soft tissue infections in the Unit-
ed States (2). An association between 
severe  CA-MRSA  infection  (e.g., 
necrotizing fasciitis and pneumonia) 
and the synergohymenotrophic exo-
toxin  Panton-Valentine  leukocidin 
(PVL) has been made (3,4). Reports 
have  documented  CA-MRSA  trans-
mission among household members; 
however, most cases have been mild 
or moderate infections or asymptom-
atic colonization (5–7). We describe 
intrafamilial transmission of a PVL-
containing  CA-MRSA  clone  com-
mon  in Australia  (ST30-MRSA-IV) 
between  a  nurse  who  experienced 
recurrent abscesses and her husband, 
who died of severe pneumonia. 
 In July 2006, a 61-year-old pre-
viously healthy nurse (Mrs A) sought 
treatment  for  an  infected  seborrheic 
cyst of the scalp. Culture of pus yield-
ed MRSA that was susceptible to clin-
damycin.  She  was  treated  with  oral 
clindamycin. After  resolution  of  the 
infection, topical MRSA decoloniza-
tion therapy with 3% hexachlorophane 
body  wash  (daily),  20%  cetrimide 
shampoo (3×/wk), and 2% mupirocin 
nasal  ointment  (3×/d)  was  adminis-
tered for 10 days, as per our institu-
tional  protocol  for  MRSA-colonized 
healthcare  workers.  Subsequently, 
MRSA  surveillance  swabs  from  the 
nose, throat, and scalp obtained week-
ly for 10 weeks and cultured on selec-
tive MRSA chromogenic agar and in 
selective broth enrichment media were 
negative.  Household  members  were 
not screened for MRSA colonization.
Six months later, in January 2007, 
the  patient’s  husband  (Mr A),  a  60-
year-old  smoker  who  was  her  only 
household contact, was admitted with 
a 1-day history of dyspnea, pleuritic 
chest pain, cough with sputum, fever, 
vomiting, and diarrhea. On admission, 
he was unwell, with tachycardia (pulse 
rate  132  bpm),  hypotension  (95/60 
mm Hg), tachypnea (40 breaths/min), 
and hypoxia (oxygen saturation 93% 
on 15 L O2/min). A chest radiograph 
showed bilateral infiltrates and a right 
pleural  effusion.  He  was  diagnosed 
with community-acquired pneumonia 
and  treated  with  intravenous  ceftri-
axone  and  azithromycin  as  per  local 
protocol.  However,  within  12  hours, 
his condition deteriorated, necessitat-
ing admission to the intensive care unit 
for ventilation and inotropic support. 
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Broncho-alveolar lavage (BAL) fluid 
demonstrated  gram-positive  cocci  in 
tetrads,  and  intravenous  vancomycin 
and dicloxacillin were added to thera-
py. Despite aggressive supportive mea-
sures, Mr A’s condition continued to 
deteriorate, and he died 28 hours after 
admission.  MRSA  was  subsequently 
cultured from blood, sputum, and BAL 
fluid; an autopsy was not performed. 
In June 2007, Mrs A sought treat-
ment for an abscess with cellulitis on 
the  left  thigh. The  abscess  was  sur-
gically  drained,  and  cultures  again 
yielded MRSA. She was treated with 
intravenous and oral clindamycin for 
10 days and subsequently underwent 
repeat MRSA decolonization therapy; 
again, swabs taken 1×/wk for 10 weeks 
postdecolonization were negative. 
Molecular  typing  of  the  MRSA 
isolates  obtained  from  Mrs A  at  the 
time of her initial skin infection, Mr 
A’s blood culture, and Mrs A’s second 
skin infection was performed by using 
contour-clamped homogenous electric 
field  electrophoresis  (CHEF)  accord-
ing to a previously described method 
(8) (Figure). The CHEF patterns were 
indistinguishable  and  were  identical 
to the known CHEF pattern for ST30-
MRSA-IV (9). All 3 isolates contained 
the  lukF-PV/lukS-PV  genes  that  en-
code PVL and had the same antibio-
gram (i.e., isolates were resistant only 
to β-lactam antimicrobial agents). 
We describe intrafamilial MRSA 
transmission  (defined  as  >2  family 
members who live at the same postal 
address and who are colonized or in-
fected with a MRSA strain having the 
same CHEF pattern) that resulted in a 
fatal outcome. The MRSA strain re-
sponsible (ST30-MRSA-IV, or West-
ern  Samoan  phage  pattern/Oceania 
strain MRSA) is a common cause of 
CA-MRSA infection in Australia. 
Recurrent  MRSA  infection  de-
veloped in Mrs A several months after 
completion  of  apparently  successful 
MRSA  decolonization  therapy.  We 
could not determine whether this re-
currence  was  because  of  persistent 
MRSA  colonization  not  detected  by 
surveillance (e.g., perineal or gastroin-
testinal colonization) or whether Mrs 
A  was  successfully  decolonized  but 
Mr A’s colonization/infection resulted 
in recolonization and subsequent in-
fection.  Whatever  the  explanation, 
this case highlights a potential weak-
ness in MRSA surveillance programs 
that  rely  on  short-term,  limited-site 
surveillance. 
 A comprehensive MRSA search-
and-destroy  policy  in  place  for  over 
25  years  has  prevented  MRSA  from 
becoming  endemic  in  our  institution 
(10).  However,  the  rapidly  changing 
epidemiology of MRSA in becoming 
a predominantly community pathogen 
represents  a  significant  challenge  to 
the ongoing success of this policy. In 
response to this challenge, the West-
ern Australian  Department  of  Health 
has implemented a community-based 
MRSA  search-and-destroy  program 
for  patients  with  MRSA  infection 
caused by exotic PVL-positive clones 
(e.g., ST30-MRSA-IV, ST93-MRSA-
IV, ST80-MRSA-IV, and ST8-MRSA-
IV/USA300).  This  program  includes 
treatment/decolonization  therapy  for 
the index case, screening of household 
members for MRSA infection/coloni-
zation, and simultaneous treatment/de-
colonization if MRSA is identified. Al-
though a similar approach has proved 
successful  in  Denmark  (6),  whether 
this  success  can  be  sustainable  on  a 
larger scale remains to be seen.  
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Figure.  Contour-clamped  homogenous  electric  field  electrophoresis  of  Staphylococcus 
aureus  isolates.  Lanes  2,  3,  and  4  (Sma1  restriction):  methicillin-resistant  S.  aureus 
(MRSA) isolated from Mrs A’s first infection, Mr A’s blood culture, and Mrs A’s second 
infection, respectively. Lanes 6, 7, and 8 (Apa1 restriction): MRSA isolated from Mrs A’s 
first infection, Mr A’s blood culture, and Mrs A’s second infection, respectively. Lanes 1, 5, 
and 9: S. aureus NCTC8325. LETTERS
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Rhombencephalitis 
and Coxsackievirus 
A16 
To the Editor: Hand, foot, and 
mouth  disease  (HFMD)  is  a  com-
mon illness in children and is mainly 
caused by coxsackievirus A16 (CA16) 
and enterovirus 71 (EV71). Although 
its clinical course is usually unevent-
ful and most patients experience a full 
recovery,  serious  neurologic  compli-
cations,  including  encephalitis,  can 
occur  secondarily  to  HFMD  caused 
by EV71. Such neurological compli-
cations occurred during an epidemic 
in  Taiwan  in  1998  (1).  Encephalitis 
caused by EV71 is characterized by 
rhombencephalitis,  which  is  a  com-
bination  of  brainstem  encephalitis 
and cerebellitis. Signs and symptoms 
of  rhombencephalitis  are  irritability, 
myoclonus, ataxia, and cranial nerve 
involvement (1). In contrast to EV71, 
HFMD caused by CA16 is associated 
with  few  neurologic  complications 
with the exception of infrequent asep-
tic meningitis (2). We report a case of 
rhombencephalitis  that  developed  in 
an infant as a complication of HFMD 
caused by CA16.
HFMD  was  diagnosed  in  a  23-
month-old  girl  on  the  basis  of  high 
fever (>40°C, 3 d duration), stomati-
tis, and multiple papules on her palms, 
soles,  and  buttocks.  Her  illness  oc-
curred in the summer of 2007, when 
sentinel surveillance in the region in-
dicated an epidemic of HFMD caused 
by  both  CA16  and  EV71.  She  was 
admitted to our hospital in Fukoka, Ja-
pan, on day 4 of illness because of ab-
normal eye movement, irritability, and 
inability to stand. She had intermittent 
to-and-fro,  horizontal  oscillations  of 
the eyes (ocular flutter). She also had 
truncal and limb ataxia and myoclonus 
in her head and limbs. Brain magnetic 
resonance imaging (MRI) showed T1-
low  and  T2-high  bulbopontine  and 
cerebellar  lesions  around  the  fourth 
ventricle  (Figure).  Peripheral  blood 
showed a mild leukocytosis (13.13 × 
109/L) and a C-reactive protein level 
within  reference  range  (0.9  mg/L). 
Blood  chemistry  results  were  unre-
markable.  Cerebrospinal  fluid  (CSF) 
examination  showed  mononuclear 
pleocytosis (74/µL) with normal pro-
tein  and  glucose  levels.  CA16  was 
isolated from her stool specimen on 
day  4  of  illness.  Based  on  reverse 
transcription–PCR, CSF was negative 
for enterovirus RNA. 
Without  specific  treatment,  our 
patient’s fever resolved on day 5 of 
illness. The myoclonus, ocular flutter, 
and  irritability  subsided  by  day  16, 
when MRI findings returned to nor-
mal. Ataxia disappeared gradually ≈1 
month after onset, and no neurologic 
sequelae occurred. Neutralizing anti-
body titers against CA16 and EV71 
on day 21 of illness were 32 and <8, 
respectively. Based on the sequence 
analysis  of  the  partial  VP1  region 
(876 bp), we classified the patient’s 
CA16 strain phylogenetically as ge-
netic lineage C (3). This lineage was 
identical to lineage 2 (4), which be-
came the dominant circulating strain 
in Asia, including Japan, after the late 
1990s (98.2% identical to the 1018T/
VNM/05  strain  isolated  in  Vietnam 
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